HemaSphere, 2023-08, Vol.7 (S3), p.e24670ab-n/a
- Shaw, Briony
- Chung, Eliza
- Wellard, Cameron
- Yoo, Edward
- Bennett, Rory
- Birks, Callum
- Johnston, Anna
- Cheah, Chan
- Hamad, Nada
- Simpson, Jock
- Barraclough, Allison
- Ku, Matthew
- Viiala, Nicholas
- Ratnasingam, Sumita
- Armytage, Tasman
- Cochrane, Tara
- Chong, Geoff
- Lee, Denise
- Manos, Kate
- Keane, Colm
- Wallwork, Stephanie
- Opat, Stephen
- Hawkes, Eliza A
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Shaw, Briony
- Chung, Eliza
- Wellard, Cameron
- Yoo, Edward
- Bennett, Rory
- Birks, Callum
- Johnston, Anna
- Cheah, Chan
- Hamad, Nada
- Simpson, Jock
- Barraclough, Allison
- Ku, Matthew
- Viiala, Nicholas
- Ratnasingam, Sumita
- Armytage, Tasman
- Cochrane, Tara
- Chong, Geoff
- Lee, Denise
- Manos, Kate
- Keane, Colm
- Wallwork, Stephanie
- Opat, Stephen
- Hawkes, Eliza A
- Titel
- P1193: POLATUZUMAB, BENDAMUSTINE & RITUXIMAB (POLA‐BR) EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RRDLBCL) TRIAL‐INELIGIBLE PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY
- Ist Teil von
- HemaSphere, 2023-08, Vol.7 (S3), p.e24670ab-n/a
- Ort / Verlag
- Philadelphia, PA: Lippincott Williams & Wilkins
- Erscheinungsjahr
- 2023
- Quelle
- EZB-FREE-00999 freely available EZB journals
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2572-9241eISSN: 2572-9241DOI: 10.1097/01.HS9.0000971668.24670.abTitel-ID: cdi_doaj_primary_oai_doaj_org_article_e44f1b2473734afd9d926812ddcf5f35
- Format
- –